Anlon Healthcare shareholders approved key strategic resolutions including an enhancement of authorized share capital and a major preferential equity issuance to acquire Apiqo Organics Private Limited and Bizotic Lifescience Private Limited. The 13th Annual General Meeting was held on September 5, 2026, via video conference.

The meeting commenced at 11:10 am and concluded at 11:50 am. Punitkumar Rasadia, Chairman and Managing Director, presided over the proceedings. A total of 31 members were present. The company submitted the voting results and consolidated scrutinizer's report to BSE Limited and the National Stock Exchange of India Ltd pursuant to Section 108 of the Companies Act, 2013, and Rule 20 of the Companies (Management and Administration) Rules, 2014.

Key Resolutions Passed

Shareholders approved ordinary and special resolutions covering financial statements, director appointments, and corporate actions. The most material decisions involved expanding the capital structure to facilitate acquisitions.

Management Overview

Punitkumar Rasadia provided an overview of the company’s operations and financial performance for the fiscal year ended March 31, 2026. Naimish Bhatt, Chief Financial Officer, welcomed members and briefed them on participation procedures. Seven registered speakers raised questions, which were addressed by the management. Detailed queries were requested via email for comprehensive responses.

The statutory auditor, M/s R V D & Co., and secretarial auditor/scrutinizer, M/s K. P. Ghelani & Associates, were present. Their reports contained no qualifications or adverse remarks.

Anlon Healthcare issued a corrigendum to its Annual General Meeting (AGM) notice on August 25, 2026, addressing observations from the Bombay Stock Exchange and National Stock Exchange regarding its proposed preferential share issue.

The company plans to hold its 13th AGM on September 5, 2026, to seek shareholder approval for the issuance and allotment of equity shares on a preferential basis. The corrigendum revises specific clauses in the notice and explanatory statement to align with regulatory requirements raised by the exchanges on August 18 and August 19, 2026.

Issue Details and Pricing

The preferential issue involves two components: an acquisition of shares from Anlon Orthoplastics Private Limited (AOPL) and a buyback-linked preferential issue (BLPL). The total value of the AOPL component is ₹1,165,179,600, while the BLPL component totals ₹367,840,000.

Shares are being allotted at a price of ₹17.85 per equity share. This pricing is based on the volume-weighted average price on the NSE during the 90 trading days preceding the relevant date, which was determined to be ₹17.78. An independent registered valuer, CA Gaurang Agarwal, confirmed this fair value in a report dated August 6, 2026.

Allotment Structure

The AOPL component involves the allotment of 6,52,76,283 shares to 159 proposed allottees. The largest single allottee in this segment is Punitkumar Rameshbhai Rasadia, who is proposed to receive 1,75,23,043 shares valued at ₹312,786,300.

The BLPL component includes the allotment of 2,06,07,334 shares to 171 proposed allottees. Sanjukumar Rajeshbhai Savani is the largest recipient in this category, with 34,82,353 shares valued at ₹62,160,000.

Promoter Subscription

Only two promoters have indicated an intention to subscribe to the offer:

• Punitkumar Rameshbhai Rasadia (Promoter and Chairman & Managing Director): 1,84,19,402 shares
• Meet Atulkumar Vachhani (Promoter and Whole Time Director): 93,51,099 shares

Shareholding Pattern Impact

Post-issue, the promoter group's shareholding is expected to decrease from 52.68% to 49.85%. Conversely, public shareholding will rise from 47.32% to 50.15%, ensuring compliance with minimum public holding norms. The total number of equity shares will increase from 53,15,15,000 to 61,73,98,617.